A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4697-4704

  Braybrooke, Jeremy P ^a   O’Byrne, Kenneth J ^a   Propper, David J ^a   Blann, Andrew ^b   Saunders, Mark ^a   Dobbs, Nicola ^a   Han, Cheng ^a   Woodhull, Jane ^a   Mitchell, Karen ^a   Crew, Jeremy ^a   Smith, Kenneth ^a   Stephens, Ross ^c   Ganesan, Trivadi S ^a   Talbot, Denis C ^a   Harris, Adrian L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GYRASE INHIBITOR; RAZOXANE; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; INOPERABLE CANCER; KIDNEY CARCINOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; URINE LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; E-SELECTIN; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RAZOXANE; RECEPTORS, CELL SURFACE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON WILLEBRAND FACTOR;

EID: 0034488576     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Chemotherapy of renal cell carcinoma: 1983-1989
2. Cancer of the kidney and ureter
3. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis
4. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
5. Recombinant human interleukin-2, recombinant interferon α-2a, or both in metastatic renal-cell carcinoma
6. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
7. Control of malignant metastases by ICRF 159
8. Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic
9. Metastases and the normalisation of tumor blood vessels by ICRF 159 a new type of drug action
10. Histological analysis of the antimetastatic effect of (±)1,2-bis(3,5-dioxopiperazine-1-yl)propane
11. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
12. ICRF 159 (+1,2-di(3,5-dioxopiperazin-1-yl)propane. N.S.C.-129943: Razoxane
13. Radiotherapeutic enhancement by razoxane
14. The bioavailability in man of ICRF-159, a new oral antineoplastic agent
15. Phase I clinical trial of a single dose and two weekly schedules of ICRF-159 (NSC-129943)
16. Randomised trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: Five year followup
17. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colorectal cancer
18. Clinical applications of research on angiogenesis
19. Renal tumors
20. Prognostic significance of microvessel count in low stage renal cell carcinoma
21. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
22. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon α administration
23. Regulation of local host-mediated anti-tumor mechanisms by cytokines: Direct and indirect effects on leukocyte recruitment and angiogenesis
24. Markedly increased amounts of messanger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinoma associated with angiogenesis
25. Induction of tubulogenesis of microvascular endothelial cells by basic fibroblastic growth factor from human SN12C renal cancer cells
26. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma
27. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma
28. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies
29. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma
30. Elevated levels of the angiogenic cytokines basis fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
31. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients
32. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
33. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy
34. The influence of age, gender and ABOblood group on soluble endothelial cell markers and adhesion molecules
35. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
36. Are angiostatin and endostatin cures for cancer?
37. Continuous low dose thalidomide: A Phase II study in advanced melanoma, renal cell, ovarian and breast cancer
38. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer
39. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
40. Interferon γ-1b compared with placebo in metastatic renal cell carcinoma
41. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
42. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer
43. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer
44. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression
45. Serum soluble vascular adhesion molecule-1: Role as a surrogate marker of angiogenesis
46. Haematologic findings in patients with renal carcinoma
47. Involvement of platelets in tumor angiogenesis?
48. 2+and von Willebrand factor release in human endothelial cells
49. Therapy-related acute promyelocytic leukaemia
50. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents